<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='72'><Row><AdverseEvent>Wegener granulomatosis</AdverseEvent><AdverseIndicationCode>1888</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="7401">Multikine</Drug><Intervention>Multikine</Intervention><MeddraAdverseEvent>Urological adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>.08</PercentAffected><ProtocolDose/><Trial id="41749"/><Units/></Row><Row><AdverseEvent>Diarrhea</AdverseEvent><AdverseIndicationCode>102</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1.8</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Gastrointestinal adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>33</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Emesis</AdverseEvent><AdverseIndicationCode>110</AdverseIndicationCode><DevelopmentStatus>Phase 2 Clinical</DevelopmentStatus><Dose>1.5</Dose><Drug id="21065">tucotuzumab celmoleukin</Drug><Intervention>EMD-273066</Intervention><MeddraAdverseEvent>Gastrointestinal adverse event</MeddraAdverseEvent><Patients>110</Patients><PercentAffected/><ProtocolDose>EMD-273066 1.5 milligram/m2 dosecyclophosphamide 300 milligram/m2 dose</ProtocolDose><Trial id="89159"/><Units>milligram/m2 dose</Units></Row><Row><AdverseEvent>Arthralgia</AdverseEvent><AdverseIndicationCode>2439</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1.8</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Neurological adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>17</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Arthralgia</AdverseEvent><AdverseIndicationCode>2439</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Neurological adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>50</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Skin rash</AdverseEvent><AdverseIndicationCode>3020</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>66</Patients><PercentAffected>47.9</PercentAffected><ProtocolDose>NHS-IL2-LT .075 milligram/kg doseNHS-IL2-LT .15 milligram/kg doseNHS-IL2-LT .225 milligram/kg dosecyclophosphamide 300 milligram/m2 doseNHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT .45 milligram/kg doseNHS-IL2-LT .6 milligram/kg doseNHS-IL2-LT .9 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.1 milligram/kg doseNHS-IL2-LT 2.5 milligram/kg doseNHS-IL2-LT 3 milligram/kg doseNHS-IL2-LT 1.2 milligram/kg doseNHS-IL2-LT 1.5 milligram/kg dose</ProtocolDose><Trial id="62646"/><Units/></Row><Row><AdverseEvent>Hypotension</AdverseEvent><AdverseIndicationCode>408</AdverseIndicationCode><DevelopmentStatus>Phase 2 Clinical</DevelopmentStatus><Dose>1.5</Dose><Drug id="21065">tucotuzumab celmoleukin</Drug><Intervention>EMD-273066</Intervention><MeddraAdverseEvent>Vascular adverse event</MeddraAdverseEvent><Patients>110</Patients><PercentAffected/><ProtocolDose>EMD-273066 1.5 milligram/m2 dosecyclophosphamide 300 milligram/m2 dose</ProtocolDose><Trial id="89159"/><Units>milligram/m2 dose</Units></Row><Row><AdverseEvent>Nausea</AdverseEvent><AdverseIndicationCode>226</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>.3</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Gastrointestinal adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>50</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Chill</AdverseEvent><AdverseIndicationCode>3050</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="86441">ALKS-4230</Drug><Intervention>ALKS-4230</Intervention><MeddraAdverseEvent/><Patients>300</Patients><PercentAffected>63</PercentAffected><ProtocolDose>ALKS-4230 .1 microgram/kg doseALKS-4230 .3 microgram/kg doseALKS-4230 1 microgram/kg doseALKS-4230 3 microgram/kg doseALKS-4230 6 microgram/kg dose</ProtocolDose><Trial id="263216"/><Units/></Row><Row><AdverseEvent>Anemia</AdverseEvent><AdverseIndicationCode>17</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="86441">ALKS-4230</Drug><Intervention>ALKS-4230</Intervention><MeddraAdverseEvent>Hematological adverse event</MeddraAdverseEvent><Patients>300</Patients><PercentAffected>33</PercentAffected><ProtocolDose>ALKS-4230 .1 microgram/kg doseALKS-4230 .3 microgram/kg doseALKS-4230 1 microgram/kg doseALKS-4230 3 microgram/kg doseALKS-4230 6 microgram/kg dose</ProtocolDose><Trial id="263216"/><Units/></Row><Row><AdverseEvent>Sepsis</AdverseEvent><AdverseIndicationCode>114</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="7401">Multikine</Drug><Intervention>Multikine</Intervention><MeddraAdverseEvent>Infection adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>.08</PercentAffected><ProtocolDose/><Trial id="41749"/><Units/></Row><Row><AdverseEvent>Dyspnea</AdverseEvent><AdverseIndicationCode>2400</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1.8</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Respiratory adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>17</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Erythema</AdverseEvent><AdverseIndicationCode>2024</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="55115">AFTVac</Drug><Intervention>AFTVac</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected/><ProtocolDose/><Trial id="37075"/><Units/></Row><Row><AdverseEvent>Nausea</AdverseEvent><AdverseIndicationCode>226</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Gastrointestinal adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>50</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Fatigue</AdverseEvent><AdverseIndicationCode>829</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="86441">ALKS-4230</Drug><Intervention>ALKS-4230</Intervention><MeddraAdverseEvent/><Patients>300</Patients><PercentAffected>42</PercentAffected><ProtocolDose>ALKS-4230 .1 microgram/kg doseALKS-4230 .3 microgram/kg doseALKS-4230 1 microgram/kg doseALKS-4230 3 microgram/kg doseALKS-4230 6 microgram/kg dose</ProtocolDose><Trial id="263216"/><Units/></Row><Row><AdverseEvent>Hyponatremia</AdverseEvent><AdverseIndicationCode>1256</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="28450">AIC-284</Drug><Intervention>BAY-50-4798</Intervention><MeddraAdverseEvent>Metabolic adverse event</MeddraAdverseEvent><Patients>30</Patients><PercentAffected/><ProtocolDose>BAY-50-4798 1.3 milligram/kg doseBAY-50-4798 2.6 milligram/kg doseBAY-50-4798 5.2 milligram/kg doseBAY-50-4798 10.4 milligram/kg doseBAY-50-4798 17.4 milligram/kg doseBAY-50-4798 26.1 milligram/kg dose</ProtocolDose><Trial id="286299"/><Units/></Row><Row><AdverseEvent>Atrial fibrillation</AdverseEvent><AdverseIndicationCode>1542</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="28450">AIC-284</Drug><Intervention>BAY-50-4798</Intervention><MeddraAdverseEvent>Cardiac adverse event</MeddraAdverseEvent><Patients>30</Patients><PercentAffected/><ProtocolDose>BAY-50-4798 1.3 milligram/kg doseBAY-50-4798 2.6 milligram/kg doseBAY-50-4798 5.2 milligram/kg doseBAY-50-4798 10.4 milligram/kg doseBAY-50-4798 17.4 milligram/kg doseBAY-50-4798 26.1 milligram/kg dose</ProtocolDose><Trial id="286299"/><Units/></Row><Row><AdverseEvent>Xerosis</AdverseEvent><AdverseIndicationCode>3868</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>66</Patients><PercentAffected>39.6</PercentAffected><ProtocolDose>NHS-IL2-LT .075 milligram/kg doseNHS-IL2-LT .15 milligram/kg doseNHS-IL2-LT .225 milligram/kg dosecyclophosphamide 300 milligram/m2 doseNHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT .45 milligram/kg doseNHS-IL2-LT .6 milligram/kg doseNHS-IL2-LT .9 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.1 milligram/kg doseNHS-IL2-LT 2.5 milligram/kg doseNHS-IL2-LT 3 milligram/kg doseNHS-IL2-LT 1.2 milligram/kg doseNHS-IL2-LT 1.5 milligram/kg dose</ProtocolDose><Trial id="62646"/><Units/></Row><Row><AdverseEvent>Wegener granulomatosis</AdverseEvent><AdverseIndicationCode>1888</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="7401">Multikine</Drug><Intervention>Multikine</Intervention><MeddraAdverseEvent>Immunological adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>.08</PercentAffected><ProtocolDose/><Trial id="41749"/><Units/></Row><Row><AdverseEvent>Headache</AdverseEvent><AdverseIndicationCode>148</AdverseIndicationCode><DevelopmentStatus>Phase 2 Clinical</DevelopmentStatus><Dose>1.5</Dose><Drug id="21065">tucotuzumab celmoleukin</Drug><Intervention>EMD-273066</Intervention><MeddraAdverseEvent>Neurological adverse event</MeddraAdverseEvent><Patients>110</Patients><PercentAffected/><ProtocolDose>EMD-273066 1.5 milligram/m2 dosecyclophosphamide 300 milligram/m2 dose</ProtocolDose><Trial id="89159"/><Units>milligram/m2 dose</Units></Row><Row><AdverseEvent>Dyspnea</AdverseEvent><AdverseIndicationCode>2400</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Respiratory adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>100</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Appetite loss</AdverseEvent><AdverseIndicationCode>3038</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="86441">ALKS-4230</Drug><Intervention>ALKS-4230</Intervention><MeddraAdverseEvent/><Patients>300</Patients><PercentAffected>25</PercentAffected><ProtocolDose>ALKS-4230 .1 microgram/kg doseALKS-4230 .3 microgram/kg doseALKS-4230 1 microgram/kg doseALKS-4230 3 microgram/kg doseALKS-4230 6 microgram/kg dose</ProtocolDose><Trial id="263216"/><Units/></Row><Row><AdverseEvent>Pneumonia</AdverseEvent><AdverseIndicationCode>360</AdverseIndicationCode><DevelopmentStatus>Phase 2b Clinical</DevelopmentStatus><Dose/><Drug id="55115">AFTVac</Drug><Intervention>AFTVac</Intervention><MeddraAdverseEvent>Respiratory adverse event</MeddraAdverseEvent><Patients>41</Patients><PercentAffected/><ProtocolDose/><Trial id="37159"/><Units/></Row><Row><AdverseEvent>Pruritus</AdverseEvent><AdverseIndicationCode>279</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>50</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Thyroid disease</AdverseEvent><AdverseIndicationCode>326</AdverseIndicationCode><DevelopmentStatus>Phase 1b Clinical</DevelopmentStatus><Dose/><Drug id="57922">NHS-IL2-LT</Drug><Intervention>EMD-521873</Intervention><MeddraAdverseEvent>Endocrine adverse event</MeddraAdverseEvent><Patients>15</Patients><PercentAffected/><ProtocolDose>EMD-521873 .15 milligram/kg doseEMD-521873 .3 milligram/kg doseEMD-521873 .45 milligram/kg dose</ProtocolDose><Trial id="51498"/><Units/></Row><Row><AdverseEvent>Fever</AdverseEvent><AdverseIndicationCode>1833</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="55115">AFTVac</Drug><Intervention>AFTVac</Intervention><MeddraAdverseEvent/><Patients>12</Patients><PercentAffected/><ProtocolDose/><Trial id="37075"/><Units/></Row><Row><AdverseEvent>Fever</AdverseEvent><AdverseIndicationCode>1833</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="86441">ALKS-4230</Drug><Intervention>ALKS-4230</Intervention><MeddraAdverseEvent/><Patients>300</Patients><PercentAffected>63</PercentAffected><ProtocolDose>ALKS-4230 .1 microgram/kg doseALKS-4230 .3 microgram/kg doseALKS-4230 1 microgram/kg doseALKS-4230 3 microgram/kg doseALKS-4230 6 microgram/kg dose</ProtocolDose><Trial id="263216"/><Units/></Row><Row><AdverseEvent>Fatigue</AdverseEvent><AdverseIndicationCode>829</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>2.4</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent/><Patients>12</Patients><PercentAffected>50</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Dizziness</AdverseEvent><AdverseIndicationCode>3454</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="86441">ALKS-4230</Drug><Intervention>ALKS-4230</Intervention><MeddraAdverseEvent>Neurological adverse event</MeddraAdverseEvent><Patients>300</Patients><PercentAffected>21</PercentAffected><ProtocolDose>ALKS-4230 .1 microgram/kg doseALKS-4230 .3 microgram/kg doseALKS-4230 1 microgram/kg doseALKS-4230 3 microgram/kg doseALKS-4230 6 microgram/kg dose</ProtocolDose><Trial id="263216"/><Units/></Row><Row><AdverseEvent>Arthralgia</AdverseEvent><AdverseIndicationCode>2439</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Musculoskeletal adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>50</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Eosinophilia</AdverseEvent><AdverseIndicationCode>1983</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="28450">AIC-284</Drug><Intervention>BAY-50-4798</Intervention><MeddraAdverseEvent>Hematological adverse event</MeddraAdverseEvent><Patients>30</Patients><PercentAffected/><ProtocolDose>BAY-50-4798 1.3 milligram/kg doseBAY-50-4798 2.6 milligram/kg doseBAY-50-4798 5.2 milligram/kg doseBAY-50-4798 10.4 milligram/kg doseBAY-50-4798 17.4 milligram/kg doseBAY-50-4798 26.1 milligram/kg dose</ProtocolDose><Trial id="286299"/><Units/></Row><Row><AdverseEvent>Erythema</AdverseEvent><AdverseIndicationCode>2024</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="55115">AFTVac</Drug><Intervention>AFTVac</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>24</Patients><PercentAffected/><ProtocolDose/><Trial id="80200"/><Units/></Row><Row><AdverseEvent>Erythema</AdverseEvent><AdverseIndicationCode>2024</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>66</Patients><PercentAffected>13</PercentAffected><ProtocolDose>NHS-IL2-LT .075 milligram/kg doseNHS-IL2-LT .15 milligram/kg doseNHS-IL2-LT .225 milligram/kg dosecyclophosphamide 300 milligram/m2 doseNHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT .45 milligram/kg doseNHS-IL2-LT .6 milligram/kg doseNHS-IL2-LT .9 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.1 milligram/kg doseNHS-IL2-LT 2.5 milligram/kg doseNHS-IL2-LT 3 milligram/kg doseNHS-IL2-LT 1.2 milligram/kg doseNHS-IL2-LT 1.5 milligram/kg dose</ProtocolDose><Trial id="62646"/><Units/></Row><Row><AdverseEvent>Nausea</AdverseEvent><AdverseIndicationCode>226</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1.8</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Gastrointestinal adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>50</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Pruritus</AdverseEvent><AdverseIndicationCode>279</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>.3</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>50</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Fatigue</AdverseEvent><AdverseIndicationCode>829</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent/><Patients>12</Patients><PercentAffected>50</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Diarrhea</AdverseEvent><AdverseIndicationCode>102</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Gastrointestinal adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>50</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Emesis</AdverseEvent><AdverseIndicationCode>110</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="86441">ALKS-4230</Drug><Intervention>ALKS-4230</Intervention><MeddraAdverseEvent>Gastrointestinal adverse event</MeddraAdverseEvent><Patients>300</Patients><PercentAffected>42</PercentAffected><ProtocolDose>ALKS-4230 .1 microgram/kg doseALKS-4230 .3 microgram/kg doseALKS-4230 1 microgram/kg doseALKS-4230 3 microgram/kg doseALKS-4230 6 microgram/kg dose</ProtocolDose><Trial id="263216"/><Units/></Row><Row><AdverseEvent>Skin rash</AdverseEvent><AdverseIndicationCode>3020</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="28450">AIC-284</Drug><Intervention>BAY-50-4798</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>30</Patients><PercentAffected/><ProtocolDose>BAY-50-4798 1.3 milligram/kg doseBAY-50-4798 2.6 milligram/kg doseBAY-50-4798 5.2 milligram/kg doseBAY-50-4798 10.4 milligram/kg doseBAY-50-4798 17.4 milligram/kg doseBAY-50-4798 26.1 milligram/kg dose</ProtocolDose><Trial id="286299"/><Units/></Row><Row><AdverseEvent>Skin rash</AdverseEvent><AdverseIndicationCode>3020</AdverseIndicationCode><DevelopmentStatus>Phase 2 Clinical</DevelopmentStatus><Dose>1.5</Dose><Drug id="21065">tucotuzumab celmoleukin</Drug><Intervention>EMD-273066</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>110</Patients><PercentAffected/><ProtocolDose>EMD-273066 1.5 milligram/m2 dosecyclophosphamide 300 milligram/m2 dose</ProtocolDose><Trial id="89159"/><Units>milligram/m2 dose</Units></Row><Row><AdverseEvent>Chronic asthenia syndrome</AdverseEvent><AdverseIndicationCode>772</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent/><Patients>66</Patients><PercentAffected>22.9</PercentAffected><ProtocolDose>NHS-IL2-LT .075 milligram/kg doseNHS-IL2-LT .15 milligram/kg doseNHS-IL2-LT .225 milligram/kg dosecyclophosphamide 300 milligram/m2 doseNHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT .45 milligram/kg doseNHS-IL2-LT .6 milligram/kg doseNHS-IL2-LT .9 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.1 milligram/kg doseNHS-IL2-LT 2.5 milligram/kg doseNHS-IL2-LT 3 milligram/kg doseNHS-IL2-LT 1.2 milligram/kg doseNHS-IL2-LT 1.5 milligram/kg dose</ProtocolDose><Trial id="62646"/><Units/></Row><Row><AdverseEvent>Palpitation</AdverseEvent><AdverseIndicationCode>1973</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="7401">Multikine</Drug><Intervention>Multikine</Intervention><MeddraAdverseEvent/><Patients>12</Patients><PercentAffected>.08</PercentAffected><ProtocolDose/><Trial id="41749"/><Units/></Row><Row><AdverseEvent>Erythema</AdverseEvent><AdverseIndicationCode>2024</AdverseIndicationCode><DevelopmentStatus>Phase 2b Clinical</DevelopmentStatus><Dose/><Drug id="55115">AFTVac</Drug><Intervention>AFTVac</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>41</Patients><PercentAffected/><ProtocolDose/><Trial id="37159"/><Units/></Row><Row><AdverseEvent>Pruritus</AdverseEvent><AdverseIndicationCode>279</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1.8</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>33</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Acidosis</AdverseEvent><AdverseIndicationCode>1020</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="7401">Multikine</Drug><Intervention>Multikine</Intervention><MeddraAdverseEvent>Metabolic adverse event</MeddraAdverseEvent><Patients/><PercentAffected>0</PercentAffected><ProtocolDose/><Trial id="41727"/><Units/></Row><Row><AdverseEvent>Fatigue</AdverseEvent><AdverseIndicationCode>829</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1.8</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent/><Patients>12</Patients><PercentAffected>33</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Constipation</AdverseEvent><AdverseIndicationCode>404</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="86441">ALKS-4230</Drug><Intervention>ALKS-4230</Intervention><MeddraAdverseEvent>Gastrointestinal adverse event</MeddraAdverseEvent><Patients>300</Patients><PercentAffected>38</PercentAffected><ProtocolDose>ALKS-4230 .1 microgram/kg doseALKS-4230 .3 microgram/kg doseALKS-4230 1 microgram/kg doseALKS-4230 3 microgram/kg doseALKS-4230 6 microgram/kg dose</ProtocolDose><Trial id="263216"/><Units/></Row><Row><AdverseEvent>Headache</AdverseEvent><AdverseIndicationCode>148</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="7401">Multikine</Drug><Intervention>Multikine</Intervention><MeddraAdverseEvent>Neurological adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>.08</PercentAffected><ProtocolDose/><Trial id="41749"/><Units/></Row><Row><AdverseEvent>Dyspnea</AdverseEvent><AdverseIndicationCode>2400</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="86441">ALKS-4230</Drug><Intervention>ALKS-4230</Intervention><MeddraAdverseEvent>Respiratory adverse event</MeddraAdverseEvent><Patients>300</Patients><PercentAffected>29</PercentAffected><ProtocolDose>ALKS-4230 .1 microgram/kg doseALKS-4230 .3 microgram/kg doseALKS-4230 1 microgram/kg doseALKS-4230 3 microgram/kg doseALKS-4230 6 microgram/kg dose</ProtocolDose><Trial id="263216"/><Units/></Row><Row><AdverseEvent>Arthralgia</AdverseEvent><AdverseIndicationCode>2439</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1.8</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Musculoskeletal adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>17</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Arthralgia</AdverseEvent><AdverseIndicationCode>2439</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>.3</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Neurological adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>100</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Arthralgia</AdverseEvent><AdverseIndicationCode>2439</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>.3</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Musculoskeletal adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>100</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Appetite loss</AdverseEvent><AdverseIndicationCode>3038</AdverseIndicationCode><DevelopmentStatus>Phase 1b Clinical</DevelopmentStatus><Dose/><Drug id="57922">NHS-IL2-LT</Drug><Intervention>EMD-521873</Intervention><MeddraAdverseEvent/><Patients>15</Patients><PercentAffected/><ProtocolDose>EMD-521873 .15 milligram/kg doseEMD-521873 .3 milligram/kg doseEMD-521873 .45 milligram/kg dose</ProtocolDose><Trial id="51498"/><Units/></Row><Row><AdverseEvent>Hypotension</AdverseEvent><AdverseIndicationCode>408</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="28450">AIC-284</Drug><Intervention>BAY-50-4798</Intervention><MeddraAdverseEvent>Vascular adverse event</MeddraAdverseEvent><Patients>30</Patients><PercentAffected/><ProtocolDose>BAY-50-4798 1.3 milligram/kg doseBAY-50-4798 2.6 milligram/kg doseBAY-50-4798 5.2 milligram/kg doseBAY-50-4798 10.4 milligram/kg doseBAY-50-4798 17.4 milligram/kg doseBAY-50-4798 26.1 milligram/kg dose</ProtocolDose><Trial id="286299"/><Units/></Row><Row><AdverseEvent>Nausea</AdverseEvent><AdverseIndicationCode>226</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="86441">ALKS-4230</Drug><Intervention>ALKS-4230</Intervention><MeddraAdverseEvent>Gastrointestinal adverse event</MeddraAdverseEvent><Patients>300</Patients><PercentAffected>33</PercentAffected><ProtocolDose>ALKS-4230 .1 microgram/kg doseALKS-4230 .3 microgram/kg doseALKS-4230 1 microgram/kg doseALKS-4230 3 microgram/kg doseALKS-4230 6 microgram/kg dose</ProtocolDose><Trial id="263216"/><Units/></Row><Row><AdverseEvent>Pruritus</AdverseEvent><AdverseIndicationCode>279</AdverseIndicationCode><DevelopmentStatus>Phase 2b Clinical</DevelopmentStatus><Dose/><Drug id="55115">AFTVac</Drug><Intervention>AFTVac</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>41</Patients><PercentAffected/><ProtocolDose/><Trial id="37159"/><Units/></Row><Row><AdverseEvent>Lymphocytopenia</AdverseEvent><AdverseIndicationCode>1992</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Hematological adverse event</MeddraAdverseEvent><Patients>66</Patients><PercentAffected>43.8</PercentAffected><ProtocolDose>NHS-IL2-LT .075 milligram/kg doseNHS-IL2-LT .15 milligram/kg doseNHS-IL2-LT .225 milligram/kg dosecyclophosphamide 300 milligram/m2 doseNHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT .45 milligram/kg doseNHS-IL2-LT .6 milligram/kg doseNHS-IL2-LT .9 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.1 milligram/kg doseNHS-IL2-LT 2.5 milligram/kg doseNHS-IL2-LT 3 milligram/kg doseNHS-IL2-LT 1.2 milligram/kg doseNHS-IL2-LT 1.5 milligram/kg dose</ProtocolDose><Trial id="62646"/><Units/></Row><Row><AdverseEvent>Fever</AdverseEvent><AdverseIndicationCode>1833</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>1.8</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent/><Patients>12</Patients><PercentAffected>50</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Fatigue</AdverseEvent><AdverseIndicationCode>829</AdverseIndicationCode><DevelopmentStatus>Phase 1b Clinical</DevelopmentStatus><Dose/><Drug id="57922">NHS-IL2-LT</Drug><Intervention>EMD-521873</Intervention><MeddraAdverseEvent/><Patients>15</Patients><PercentAffected/><ProtocolDose>EMD-521873 .15 milligram/kg doseEMD-521873 .3 milligram/kg doseEMD-521873 .45 milligram/kg dose</ProtocolDose><Trial id="51498"/><Units/></Row><Row><AdverseEvent>Dermatological disease</AdverseEvent><AdverseIndicationCode>95</AdverseIndicationCode><DevelopmentStatus>Phase 2b Clinical</DevelopmentStatus><Dose/><Drug id="55115">AFTVac</Drug><Intervention>AFTVac</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>41</Patients><PercentAffected/><ProtocolDose/><Trial id="37159"/><Units/></Row><Row><AdverseEvent>Myalgia</AdverseEvent><AdverseIndicationCode>1039</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="86441">ALKS-4230</Drug><Intervention>ALKS-4230</Intervention><MeddraAdverseEvent>Musculoskeletal adverse event</MeddraAdverseEvent><Patients>300</Patients><PercentAffected>21</PercentAffected><ProtocolDose>ALKS-4230 .1 microgram/kg doseALKS-4230 .3 microgram/kg doseALKS-4230 1 microgram/kg doseALKS-4230 3 microgram/kg doseALKS-4230 6 microgram/kg dose</ProtocolDose><Trial id="263216"/><Units/></Row><Row><AdverseEvent>Diarrhea</AdverseEvent><AdverseIndicationCode>102</AdverseIndicationCode><DevelopmentStatus>Phase 2a Clinical</DevelopmentStatus><Dose>.3</Dose><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Gastrointestinal adverse event</MeddraAdverseEvent><Patients>12</Patients><PercentAffected>50</PercentAffected><ProtocolDose>NHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT 1 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.4 milligram/kg doseNHS-IL2-LT 3.6 milligram/kg dose</ProtocolDose><Trial id="159844"/><Units>milligram/kg dose</Units></Row><Row><AdverseEvent>Skin rash</AdverseEvent><AdverseIndicationCode>3020</AdverseIndicationCode><DevelopmentStatus>Phase 1b Clinical</DevelopmentStatus><Dose/><Drug id="57922">NHS-IL2-LT</Drug><Intervention>EMD-521873</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>15</Patients><PercentAffected/><ProtocolDose>EMD-521873 .15 milligram/kg doseEMD-521873 .3 milligram/kg doseEMD-521873 .45 milligram/kg dose</ProtocolDose><Trial id="51498"/><Units/></Row><Row><AdverseEvent>Erythema</AdverseEvent><AdverseIndicationCode>2024</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="55115">AFTVac</Drug><Intervention>AFTVac</Intervention><MeddraAdverseEvent>Dermatological adverse event</MeddraAdverseEvent><Patients>24</Patients><PercentAffected/><ProtocolDose/><Trial id="67525"/><Units/></Row><Row><AdverseEvent>Hypertension</AdverseEvent><AdverseIndicationCode>178</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="86441">ALKS-4230</Drug><Intervention>ALKS-4230</Intervention><MeddraAdverseEvent>Vascular adverse event</MeddraAdverseEvent><Patients>300</Patients><PercentAffected>21</PercentAffected><ProtocolDose>ALKS-4230 .1 microgram/kg doseALKS-4230 .3 microgram/kg doseALKS-4230 1 microgram/kg doseALKS-4230 3 microgram/kg doseALKS-4230 6 microgram/kg dose</ProtocolDose><Trial id="263216"/><Units/></Row><Row><AdverseEvent>Lymphocytopenia</AdverseEvent><AdverseIndicationCode>1992</AdverseIndicationCode><DevelopmentStatus>Phase 2 Clinical</DevelopmentStatus><Dose>1.5</Dose><Drug id="21065">tucotuzumab celmoleukin</Drug><Intervention>EMD-273066</Intervention><MeddraAdverseEvent>Hematological adverse event</MeddraAdverseEvent><Patients>110</Patients><PercentAffected/><ProtocolDose>EMD-273066 1.5 milligram/m2 dosecyclophosphamide 300 milligram/m2 dose</ProtocolDose><Trial id="89159"/><Units>milligram/m2 dose</Units></Row><Row><AdverseEvent>Fever</AdverseEvent><AdverseIndicationCode>1833</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent/><Patients>66</Patients><PercentAffected>39.6</PercentAffected><ProtocolDose>NHS-IL2-LT .075 milligram/kg doseNHS-IL2-LT .15 milligram/kg doseNHS-IL2-LT .225 milligram/kg dosecyclophosphamide 300 milligram/m2 doseNHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT .45 milligram/kg doseNHS-IL2-LT .6 milligram/kg doseNHS-IL2-LT .9 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.1 milligram/kg doseNHS-IL2-LT 2.5 milligram/kg doseNHS-IL2-LT 3 milligram/kg doseNHS-IL2-LT 1.2 milligram/kg doseNHS-IL2-LT 1.5 milligram/kg dose</ProtocolDose><Trial id="62646"/><Units/></Row><Row><AdverseEvent>Hypotension</AdverseEvent><AdverseIndicationCode>408</AdverseIndicationCode><DevelopmentStatus>Phase 1 Clinical</DevelopmentStatus><Dose/><Drug id="57922">NHS-IL2-LT</Drug><Intervention>NHS-IL2-LT</Intervention><MeddraAdverseEvent>Vascular adverse event</MeddraAdverseEvent><Patients>66</Patients><PercentAffected>31.2</PercentAffected><ProtocolDose>NHS-IL2-LT .075 milligram/kg doseNHS-IL2-LT .15 milligram/kg doseNHS-IL2-LT .225 milligram/kg dosecyclophosphamide 300 milligram/m2 doseNHS-IL2-LT .3 milligram/kg doseNHS-IL2-LT .45 milligram/kg doseNHS-IL2-LT .6 milligram/kg doseNHS-IL2-LT .9 milligram/kg doseNHS-IL2-LT 1.8 milligram/kg doseNHS-IL2-LT 2.1 milligram/kg doseNHS-IL2-LT 2.5 milligram/kg doseNHS-IL2-LT 3 milligram/kg doseNHS-IL2-LT 1.2 milligram/kg doseNHS-IL2-LT 1.5 milligram/kg dose</ProtocolDose><Trial id="62646"/><Units/></Row><Row><AdverseEvent>Pneumonia</AdverseEvent><AdverseIndicationCode>360</AdverseIndicationCode><DevelopmentStatus>Phase 2b Clinical</DevelopmentStatus><Dose/><Drug id="55115">AFTVac</Drug><Intervention>AFTVac</Intervention><MeddraAdverseEvent>Infection adverse event</MeddraAdverseEvent><Patients>41</Patients><PercentAffected/><ProtocolDose/><Trial id="37159"/><Units/></Row><Row><AdverseEvent>Abdominal pain</AdverseEvent><AdverseIndicationCode>3472</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="86441">ALKS-4230</Drug><Intervention>ALKS-4230</Intervention><MeddraAdverseEvent>Neurological adverse event</MeddraAdverseEvent><Patients>300</Patients><PercentAffected>21</PercentAffected><ProtocolDose>ALKS-4230 .1 microgram/kg doseALKS-4230 .3 microgram/kg doseALKS-4230 1 microgram/kg doseALKS-4230 3 microgram/kg doseALKS-4230 6 microgram/kg dose</ProtocolDose><Trial id="263216"/><Units/></Row><Row><AdverseEvent>Hepatotoxicity drug-induced</AdverseEvent><AdverseIndicationCode>1087</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="57607">ALT-801 (bolus injection, cancer), Altor</Drug><Intervention>ALT-801 (bolus injection, cancer), Altor</Intervention><MeddraAdverseEvent/><Patients>52</Patients><PercentAffected/><ProtocolDose>gemcitabine 1000 milligram/m2 doseALT-801 (bolus injection, cancer), Altor .08 milligram/kg doseALT-801 (bolus injection, cancer), Altor .06 milligram/kg doseALT-801 (bolus injection, cancer), Altor .04 milligram/kg dose</ProtocolDose><Trial id="88603"/><Units/></Row><Row><AdverseEvent>Myalgia</AdverseEvent><AdverseIndicationCode>1039</AdverseIndicationCode><DevelopmentStatus>Phase 1/Phase 2 Clinical</DevelopmentStatus><Dose/><Drug id="86441">ALKS-4230</Drug><Intervention>ALKS-4230</Intervention><MeddraAdverseEvent>Neurological adverse event</MeddraAdverseEvent><Patients>300</Patients><PercentAffected>21</PercentAffected><ProtocolDose>ALKS-4230 .1 microgram/kg doseALKS-4230 .3 microgram/kg doseALKS-4230 1 microgram/kg doseALKS-4230 3 microgram/kg doseALKS-4230 6 microgram/kg dose</ProtocolDose><Trial id="263216"/><Units/></Row></Rowset>